<DOC>
	<DOCNO>NCT01218750</DOCNO>
	<brief_summary>The purpose study evaluate safety end efficacy combine phakoemulsification vitrectomy retinal endophotocoagulation intraoperative use bevacizumab patient diffuse diabetic macular edema ( DDME ) , determine possible preoperative intraoperative factor might influence surgical outcome .</brief_summary>
	<brief_title>Triple Therapy Diffuse Diabetic Macular Edema</brief_title>
	<detailed_description>The pathogenesis diabetic macular edema multiple . Therefore treatment disease combine . VEGF involved pathogenesis diabetic macular edema recently anti-VEGF agent bevacizumab show beneficial treatment retinal disorder . However , endogenous VEGF require visual function . Growing body evidence indicate VEGF act also nonvascular cell , play survival role Muller cell photoreceptors . Therefore anti-VEGF therapy administer caution persistent . Photocoagulation nonperfused area eliminate increase production VEGF , proliferation RPE increase production PEDF surround impact laser area . Vitrectomy ILM peel reliefs traction macula , improve oxygenation macula lead decrease vascular permeability subsequent resolution decrease DME . Removed ILM contain part Müller cell endfeet horizontal gliosis . It likely proliferation GFAP-stained gliofibrils , observe microdamaged Müller cell , preserve blood-retinal barrier , reinforce architectural cohesion , oppose installation edema . Therefore , make hypothesis combined triple therapy effective decrease macular thickness improvement vision eye diffuse diabetic macular edema . It important surgeon determine factor might influence surgical outcome patient choose procedure get benefit . Therefore , evaluate possible preoperative intraoperative factor might influence surgical outcome</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1. diagnosis DDME clinical exam , definite retinal thickening involve center macula , confirm fluorescein angiography , without PVD , 2 . BCVA 0,3 bad log MAR unit ( &lt; =70 ETDRS letter ) 1,5 good log MAR unit ( &gt; =10 ETRDS letter ) , 3. mean central macular thickness great 250 μm optic coherence tomography ( OCT ) , 4. presence vitreomacular traction thicken taut posterior hyaloid presence epimacular membrane . 1. significant macular ischemia define enlarged perifoveal capillary loss ( &gt; 1000 µm ) fluorescein angiography , 2. focal macular edema due focal leakage microaneurysm , 3. ophthalmic disorder associate macular edema , uveitis , branch central retinal vein occlusion pseudophakic cystoid macular edema , 4. vitreous hemorrhage tractional retinal detachment secondary diabetic retinopathy , 5. ocular condition present , visual acuity would improve resolution macular edema ( e.g. , foveal atrophy , pigmentary abnormality , dense subfoveal hard exudate ) , 6. history retinal macular photocoagulation , intravitreal corticosteroid , treatment DME within 3 month prior enrollment , 7. history intraocular surgery within prior 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>DDME , ppV , ILM peeling , bevacizumab injection</keyword>
</DOC>